Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
about
Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot studyNonhuman primate models for HIV/AIDS vaccine developmentThe evolution of poxvirus vaccinesSynthetic DNA vaccine strategies against persistent viral infectionsRecombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus MacaquesPrevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gelDifferent patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trialLimited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimenProtection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccinesFactors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVVaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesMucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunityImmunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectorsMycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiencyInduction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesSystemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccinePathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.Qualitative and quantitative characteristics of rotavirus-specific CD8 T cells vary depending on the route of infection.Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques.High frequency of virus-specific CD8+ T cells in the central nervous system of macaques chronically infected with simian immunodeficiency virus SIVmac251.
P2860
Q24802232-AC6F7F07-2EF3-477B-A0B8-73CD58F29EA9Q26861148-245AACB9-2F94-4238-924B-BE0C68B7233CQ26995905-DCDD8C06-8A4D-4364-B974-2105B616096BQ27016078-F7B929A2-06C0-4781-8AB9-6989BA9DD3FAQ27491052-27201964-7AC1-4B34-B11C-D8A6DBAD902BQ28473376-D4AB3BC2-A58A-4FB6-A732-15DB9A53E235Q30330620-BCFB4183-9705-4B90-AA53-7462504C4DC6Q30532861-20CDBCFC-6EF9-48C6-AF5C-50BDDA4252DDQ33639684-02FB9778-9388-493D-A2F0-2213E9A77E37Q33644522-B5E674F0-48D4-4CDA-9640-65B0F5ED4EBCQ33649657-81EBA840-456D-423E-A718-A13E1F900FA7Q33755041-A87D87C3-C571-41F0-B4D3-D035AFE9B1E8Q33799497-4D8DE969-8A0F-47EB-82C6-44F3B6F750DCQ33800033-96ACBAE0-3557-4ABB-B2A5-6D7614B78CE4Q33810277-1DF9BC45-8BBD-4FDD-89BA-80BD9781DDB5Q33814150-55FE8522-220E-4626-BB73-7D97FC2CBE99Q33819493-1B7083A5-A61D-431C-A9F8-E3294E63A0F8Q33823503-551AE280-804D-4613-AFCD-F16945E45993Q33842383-C5C7F4C5-47B0-4353-8B92-3428FCA8CC15Q33852720-11742390-7004-4C10-93EA-9F3330C224CEQ33883995-09AE190B-DFB2-4A5F-AE6E-B504CA547E99Q34326532-6434CE50-77BE-4FFD-B32A-CA6CFF79FCDFQ34326613-4C24AD42-976B-4852-BD11-60C93E68D4B4Q34333402-EF384503-315C-42C4-AB7D-6AA328A7F095Q34339609-2BC2A3A3-3FF2-4904-BB78-F721132192DBQ34348640-FBC55909-8A37-4DEF-947F-AE1CE1D0FE4EQ34355037-9179D2BB-8967-40D1-9F7B-F1249D825E21Q34358162-7C1ECCC2-5315-4EAC-86E3-52E7497F950DQ34465510-78B91728-34D4-49AC-95E5-A49AA48ECA86Q34546037-96CC30AB-5480-469F-BD11-1F68D596B031Q34651604-8A0255A0-0131-44D0-B6FB-04F628F744E3Q35182076-6926A33A-3DF2-46B9-895F-DF62638A4184Q36141586-065EDDC0-EB27-4507-AB71-C19660257958Q36154787-1227DCB4-2017-4362-8DDB-07E9EA1DB613Q36498186-75B253C4-5E05-498A-8EA1-6C67A014A794Q36510009-98B24B54-3200-4034-B31F-D8B21E5E2E81Q36539997-78CE9CE0-CB7D-4E28-AF3B-5697C9DC2FF1Q36747697-4D47D724-53F3-4D7B-A629-24B0718079D3Q36754296-BA0486FE-0B5B-4B22-9912-FCB139581389Q36890075-5A30B302-ED36-465F-B976-9C04ACA717F3
P2860
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@ast
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@en
type
label
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@ast
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@en
prefLabel
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@ast
Recombinant vaccine-induced pr ...... n route of challenge exposure.
@en
P2093
P2860
P1433
P1476
Recombinant vaccine-induced pr ...... on route of challenge exposure
@en
P2093
C Chougnet
D Montefiori
E Paoletti
G Franchini
J Tartaglia
P2860
P304
P577
1998-05-01T00:00:00Z